Product information and disease description Place of product in therapy Approaches to treatment Current treatment options and standard of care

Antidepressants and other psychiatric pharmacotherapy

7 evidence topics · 6 sources

EHDN international guideline: depression, irritability, and anxiety

“An antidepressant may be suggested if depression occurs in HD (Grade B)” (opens the source at this quote in a new tab)
“It is recommended to use a selective SSRI or a serotonin noradrenaline reuptake inhibitor (SNRI), or alternatively Mianserin or Mirtazapine, in case of sleep disruption.” (opens the source at this quote in a new tab)
“Whilst SSRIs are first lines for irritability (Grade C)” (opens the source at this quote in a new tab)
“SSRI or SNRI are first line treatments of anxiety, especially when associated with depression.” (opens the source at this quote in a new tab)

EHDN international guideline: suicide risk assessment

“Suicide risk should be assessed in HD irrespective of the stage, being particularly vigilant at the time of diagnosis and when the disease starts to impact on day-to-day life.” (opens the source at this quote in a new tab)

HDSA physician's guide: pharmacotherapy for depression

“There is no single preferred antidepressant for treating depression in HD.” (opens the source at this quote in a new tab)

German Neurological Society guideline: psychiatric symptoms

“There is hardly any data from RCTs or controlled studies on treating mental health problems in HD. Recommendations are therefore based on expert opinion.” (opens the source at this quote in a new tab)

Expert-based consensus guidelines on agitation, anxiety, apathy, psychosis, and sleep disorders

“An international committee of 11 multidisciplinary experts proposed a series of statements regarding the description and management of each symptom.” (opens the source at this quote in a new tab)
“High-level agreement (≥85% experts strongly agreed or agreed) was reached for 107 of the 110 statements that have been incorporated into the expert-based clinical recommendations presented herein.” (opens the source at this quote in a new tab)

Systematic review of pharmacological treatment of neuropsychiatric symptoms

“Fifteen articles qualified for critical evaluation: 10 randomized controlled trials (RCTs) (five placebo-controlled and five cross-over) and five open label studies.” (opens the source at this quote in a new tab)
“As a result, convincing evidence that could guide clinical practice is lacking.” (opens the source at this quote in a new tab)

MDS evidence-based review: psychiatric symptoms

“There was no eligible evidence to support the use of specific treatments for depression, psychosis, irritability, apathy, or suicidality.” (opens the source at this quote in a new tab)